PSEN1 encodes presenilin-1, a subunit of γ-secretase, the aspartyl protease responsible for Aβ generation. More than 300 mutations in PSEN1 have been reported and mutations in PSEN1 are the most ...

To satisfy the incessant energy demands of their thousands of synapses, neurons have to have enormous supplies of ATP at the ready. Where does this seemingly bottomless well of energy come from? It’s ...

This widely used tauopathy model was developed at the University of Pennsylvania School of Medicine by Virginia Lee, John Trojanowski, and colleagues. As first reported in 2007 on a mixed background, ...

As reported in 1994, the original SOD1-G93A strain, designated G1, expressed approximately 18 copies of human SOD1, randomly inserted into the genome (Gurney et al., 1994). An unequal crossover event ...

Research News Parkinsonian disorders are difficult to diagnose. Clinical symptoms often overlap ...

Postdoctoral Position- Neurobiology of Parkinson’s Disease JOB 2025-07-09 Employer Université Laval Contact [email protected] Description The team specializes in the study of ...

Biogen’s hopes for a quick regulatory approval of its anti-Aβ antibody aducanumab may be dimming. An advisory panel convened by the U.S. Food and Drug Administration was unimpressed by the evidence ...

Scientists from academia, pharmaceutical companies, and healthcare analysis firms reached no consensus on a threshold for meaningfulness, but broadly agreed that meaningfulness should be determined ...

This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...

In a Phase 2 trial, donanemab completely cleared plaque in two-thirds of participants. Their cognitive decline slowed by a third, meeting the primary endpoint. The treatment appeared to nudge down ...

Series - Alzheimer's Association International Conference - 2021: Part 1 of 14: Aducanumab: Will Appropriate-Use Recommendations Speed Uptake? Part 2 of 14: On Donanemab, Plaques Plummet. Off ...

What do Alzheimer’s researchers think? They still have many questions about aducanumab. Most believe that the antibody slows progression of the underlying amyloid pathology. But they doubt whether ...